08/08/2026
Dal congresso GlomCon Hawaii's risultati molto favorevoli nel trattamento della nefropatia da depositi di IgA.
Sibeprenlimab in IgA Nephropathy: Topline 24-Month eGFR Results
The VISIONARY Phase 3 trial (N=510) showed sibeprenlimab preserved kidney function over 24 months, with eGFR essentially stable (+1.3 mL/min/1.73 m²) against a steady decline on placebo (-7.9 mL/min/1.73 m²), the largest eGFR benefit reported to date in a Phase 3 IgA nephropathy trial and one that meets the 2025 KDIGO treatment goal. Effects held consistent across subgroups, and safety remained favorable, with similar rates of adverse events and infections between groups and no treatment-related deaths.
The session streamed live to the public on YouTube and is available at
GlomCon Hawaii 2026 | Late-Breaking Clinical Trial SessionSibepre...